Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

Enhancing tumor T cell infiltration to enable cancer immunotherapy

(2019) Jin Zhang et al.   Immunotherapy

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

(2018) Jang Hwan Cho et al.   CELL

Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer

(2018) Jiangchuan He et al.   CELLULAR IMMUNOLOGY

Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts

(2018) Ping-Pin Zheng et al.   DRUG DISCOVERY TODAY

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients

(2018) Katherine T. Marcucci et al.   MOLECULAR THERAPY

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells

(2018) Wei Xiong et al.   MOLECULAR THERAPY

IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

(2018) Keishi Adachi et al.   NATURE BIOTECHNOLOGY

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

(2018) Theodoros Giavridis et al.   NATURE MEDICINE

A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects

(2018) Yuki Kagoya et al.   NATURE MEDICINE

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity

(2018) A. J. Davenport et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CAR-T cells: the long and winding road to solid tumors

(2018) Maria Michela D’Aloia et al.   Cell Death & Disease

Programming CAR-T cells to kill cancer

(2018) Louai Labanieh et al.   Nature Biomedical Engineering

Strategies to Address Chimeric Antigen Receptor Tonic Signaling

(2018) Adam Ajina et al.   MOLECULAR CANCER THERAPEUTICS

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

(2018) Sarwish Rafiq et al.   NATURE BIOTECHNOLOGY

Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

(2018) Alexander I. Salter et al.   Science Signaling

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+and CD30−Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions

(2018) Lee K. Hong et al.   Cancer Immunology Research

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma

(2018) Felicitas Rataj et al.   Frontiers in Immunology

Teaching an old dog new tricks: next-generation CAR T cells

(2018) Nicholas Tokarew et al.   BRITISH JOURNAL OF CANCER

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory

(2018) Sophie Viaud et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

(2018) Michael M. Boyiadzis et al.   Journal for ImmunoTherapy of Cancer

Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains

(2017) Daniel T. Harris et al.   JOURNAL OF IMMUNOLOGY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells

(2017) Dominik Bachmann et al.   Oncotarget

CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes

(2017) Zhilong Zhao et al.   Oncotarget

A versatile system for rapid multiplex genome-edited CAR T cell generation

(2017) Jiangtao Ren et al.   Oncotarget

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

(2017) Levi J. Rupp et al.   Scientific Reports

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

(2017) Diogo Gomes-Silva et al.   Cell Reports

Human Tumor Antigens Yesterday, Today, and Tomorrow

(2017) Olivera J. Finn   Cancer Immunology Research

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

(2017) Yongping Zhang et al.   Frontiers of Medicine

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia

(2016) Paulina J. Paszkiewicz et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

(2016) Partow Kebriaei et al.   JOURNAL OF CLINICAL INVESTIGATION

Structural Basis and Functional Role of Intramembrane Trimerization of the Fas/CD95 Death Receptor

(2016) Qingshan Fu et al.   MOLECULAR CELL

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors

(2016) Daniel T. Harris et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies

(2015) M. Mamonkin et al.   BLOOD

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

(2015) X. Liu et al.   CANCER RESEARCH

Erratum: The role of CD95 and CD95 ligand in cancer

(2015) M E Peter et al.   CELL DEATH AND DIFFERENTIATION

How Do Cytotoxic Lymphocytes Kill Cancer Cells?

(2015) L. Martinez-Lostao et al.   CLINICAL CANCER RESEARCH

Challenges and opportunities of allogeneic donor-derived CAR T cells

(2015) Yinmeng Yang et al.   CURRENT OPINION IN HEMATOLOGY

Designing chimeric antigen receptors to effectively and safely target tumors

(2015) Michael C Jensen et al.   CURRENT OPINION IN IMMUNOLOGY

Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time

(2015) Misty R. Jenkins et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy

(2015) Julien Valton et al.   MOLECULAR THERAPY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

Adoptive cellular therapy: A race to the finish line

(2015) Carl H. June et al.   Science Translational Medicine

Engineering CAR-T cells: Design concepts

(2015) Shivani Srivastava et al.   TRENDS IN IMMUNOLOGY

CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells

(2015) Alexander J. Davenport et al.   Cancer Immunology Research

Individual Motile CD4 + T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells

(2015) Ivan Liadi et al.   Cancer Immunology Research

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD

(2015) A. Kunkele et al.   Cancer Immunology Research

C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer

(2015) Moritz Rapp et al.   OncoImmunology

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

(2014) S. Guedan et al.   BLOOD

Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFN 

(2014) A. Textor et al.   CANCER RESEARCH

Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane

(2014) S. E. James et al.   JOURNAL OF IMMUNOLOGY

Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer

(2014) Sebastian Kobold et al.   JNCI-Journal of the National Cancer Institute

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection

(2014) P. R. Kumaresan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Chemokines in Cancer

(2014) M. T. Chow et al.   Cancer Immunology Research

The Immunological Synapse

(2014) M. L. Dustin   Cancer Immunology Research

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

(2014) Tessa Gargett et al.   Frontiers in Pharmacology

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

(2013) G. P. Linette et al.   BLOOD

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

(2013) H. Torikai et al.   BLOOD

Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction

(2013) S R Witting et al.   GENE THERAPY

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

(2013) Markus Chmielewski et al.   IMMUNOLOGICAL REVIEWS

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

(2013) Richard A. Morgan et al.   JOURNAL OF IMMUNOTHERAPY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells

(2013) P. J. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

(2013) S. Zhong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

(2013) Thomas Gaj et al.   TRENDS IN BIOTECHNOLOGY

Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation

(2013) H. Walczak   Cold Spring Harbor Perspectives in Biology

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

(2013) Zakaria Grada et al.   Molecular Therapy-Nucleic Acids

Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma

(2013) Aizea Morales-Kastresana et al.   Journal for ImmunoTherapy of Cancer

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

(2012) H. Torikai et al.   BLOOD

Minicircle DNA electrotransfer for efficient tissue-targeted gene delivery

(2012) S Chabot et al.   GENE THERAPY

Biophysical mechanism of T-cell receptor triggering in a reconstituted system

(2012) John R. James et al.   NATURE

The determination and interpretation of the therapeutic index in drug development

(2012) Patrick Y. Muller et al.   NATURE REVIEWS DRUG DISCOVERY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural Basis for Sequence-Specific Recognition of DNA by TAL Effectors

(2012) D. Deng et al.   SCIENCE

The Two Faces of Interferon-  in Cancer

(2011) M. R. Zaidi et al.   CLINICAL CANCER RESEARCH

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable

(2011) David Hassin et al.   IMMUNOLOGY

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

(2011) Sid P. Kerkar et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

(2010) C. H. J. Lamers et al.   BLOOD

Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

(2010) S. P. Kerkar et al.   CANCER RESEARCH

Targeting DNA Double-Strand Breaks with TAL Effector Nucleases

(2010) M. Christian et al.   GENETICS

Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function

(2010) D. A. Schmid et al.   JOURNAL OF IMMUNOLOGY

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

A Transposon and Transposase System for Human Application

(2010) Perry B Hackett et al.   MOLECULAR THERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

Preassembled zinc-finger arrays for rapid construction of ZFNs

(2010) Seokjoong Kim et al.   NATURE METHODS

ITAM-mediated Signaling by the T-Cell Antigen Receptor

(2010) P. E. Love et al.   Cold Spring Harbor Perspectives in Biology

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments

(2009) Michelle R. Simpson-Abelson et al.   CLINICAL IMMUNOLOGY

Switch from perforin-expressing to perforin-deficient CD8+T cells accounts for two distinct types of effector cytotoxic T lymphocytesin vivo

(2009) Avihai Meiraz et al.   IMMUNOLOGY